EP Patent

EP3149000B1 — Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Assigned to Rhizen Pharmaceuticals AG · Expires 2021-06-30 · 5y expired

What this patent protects

Patent listed against umbralisib-tosylate.

Drugs covered by this patent

umbralisib-tosylate (UMBRALISIB TOSYLATE)

Patent Metadata

Patent number: EP3149000B1
Jurisdiction: EP
Classification: —
Expires: 2021-06-30
Drug substance claim: No
Drug product claim: No
Assignee: Rhizen Pharmaceuticals AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.